Compare BMEA & JLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMEA | JLS |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.1M | 90.1M |
| IPO Year | 2021 | 2009 |
| Metric | BMEA | JLS |
|---|---|---|
| Price | $0.60 | $16.12 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $6.57 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 26.3K |
| Earning Date | 11-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.33% |
| EPS Growth | ★ 69.19 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.58 | $16.01 |
| 52 Week High | $2.24 | $18.94 |
| Indicator | BMEA | JLS |
|---|---|---|
| Relative Strength Index (RSI) | 22.67 | 36.66 |
| Support Level | N/A | $16.01 |
| Resistance Level | $1.47 | $16.57 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 2.92 | 10.89 |
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. The Fund's investment objective is to provide a high level of current income.